Keros Therapeutics (NASDAQ:KROS) Stock Price Down 8.9% – What’s Next?

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) fell 8.9% during mid-day trading on Monday . The company traded as low as $13.07 and last traded at $13.26. 220,614 shares changed hands during mid-day trading, a decline of 72% from the average session volume of 795,165 shares. The stock had previously closed at $14.56.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. BTIG Research downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. TD Cowen lowered shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Guggenheim downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, December 16th. Finally, Jefferies Financial Group initiated coverage on Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating on the stock. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Keros Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $75.00.

Keros Therapeutics Trading Down 13.0 %

The firm has a 50-day moving average of $41.71 and a two-hundred day moving average of $48.34. The firm has a market cap of $512.82 million, a price-to-earnings ratio of -2.43 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million for the quarter. During the same period in the previous year, the business posted ($1.33) EPS. The firm’s revenue was up 4750.0% on a year-over-year basis. As a group, equities analysts anticipate that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in KROS. KBC Group NV raised its holdings in Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after acquiring an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares in the last quarter. Values First Advisors Inc. bought a new stake in shares of Keros Therapeutics in the 3rd quarter valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Keros Therapeutics in the 2nd quarter worth approximately $128,000. Finally, LMR Partners LLP acquired a new position in shares of Keros Therapeutics in the 3rd quarter worth approximately $213,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.